Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 14-20

  McAlpine, Donald E ^a   Biernacka, Joanna M ^a   Mrazek, David A ^a   O'Kane, Dennis J ^a   Stevens, Susanna R ^a   Langman, Loralie J ^a   Courson, Vicki L ^a   Bhagia, Jyoti ^a   Moyer, Thomas P ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

CYP2C19; CYP2D6; genotype; O desmethyl venlafaxine; poor metabolizer

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; O DESMETHYL VENLAFAXINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ALLELE; ARTICLE; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENDER; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 78751642155     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181fcf94d     Document Type: Article

References (30)

1. Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci. 2001;2:343-351.
2. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509.
3. Lee SI, Keltner NL. Biological perspectives. Serotonin and norepineph-rine reuptake inhibitors (SNRIs): venlafaxine and duloxetine. Perspect Psychiatr Care. 2006;42:144-148.
4. Alexanderson B, Evans DA, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ. 1969;4:764-768.
5. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003; 348:529-537.
6. Black JL 3rd, O'Kane DJ, Mrazek DA. The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin Drug Metab Toxicol. 2007;3:21-31.
7. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
8. Fukuda T, Yamamoto I, Nishida Y, et al. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999;47:450-453.
9. Dalen P, Dahl ML, Bernal Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998;63:444-452.
10. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
11. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety. 2000;12(Suppl 1):30-44.
12. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999; 20:480-490.
13. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit. 2005;27:478-483.
14. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998;7(Suppl 1):24-32.
15. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit. 2000;22:202-208.
16. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med. 2008;28:619-626.
17. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206-1227.
18. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49:280-294.
19. Hermann M, Hendset M, Fosaas K, et al. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desme- thylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol. 2008;64:483-487.
20. Fukuda T, Nishida Y, Zhou Q, et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol. 2000;56:175-180.
21. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004;60:329-336.
22. McAlpine DE, O'Kane DJ, Black JL, et al. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc. 2007;82: 1065-1068.
23. Zhu Z, Neirinck L. High-performance liquid chromatography-mass spectrometry method for the determination of paroxetine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;780: 295-300. (Pubitemid 35223565)
24. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234-242.
25. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11:573-585.
26. Reis M, Lundmark J, Bjork H, et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit. 2002;24:545-553. (Pubitemid 34857910)
27. Kootstra-Ros JE, Van Weelden MJ, Hinrichs JW, et al. Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J Clin Pharmacol. 2006;46:1320-1327.
28. Charlier C, Pinto E, Ansseau M, et al. Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipr-amine, paroxetine or venlafaxine. Hum Psychopharmacol. 2000;15: 453-459.
29. Charlier C, Pinto E, Ansseau M, et al. Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol. 2002;16:369-372.
30. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193-202.